Changchun Qijian was established in June 5438+February 2003, and Changchun Institute of Biological Products was established in June 5438 +0946, both of which are subsidiaries of China Biotechnology Co., Ltd.
Qijian Bio's registered address is Torch Road 1 in Changchun High-tech Development Zone, with an area of 30,000 square meters and a registered capital of140 million yuan. It is one of the top 50 high-tech enterprises in Changchun, and one of the top ten outstanding contribution enterprises in fiscal and taxation development in Changchun New District.
The main product is live attenuated varicella vaccine, which is the first domestic production and export enterprise, and also the enterprise with the largest number of varicella vaccines listed, with a market share of about 22% in 20 19. Products are exported to South Korea, India and C? te d 'Ivoire.
Note: Sinopharm China Bio immediately responded to the replacement of vaccination certificate by the manufacturer. The reason why Sinopharm became Changchun Biological, even Lanzhou Biological and Chengdu Biological was that Sinopharm Group further ensured the vaccine supply in COVID-19, expanded the vaccine production and met the vaccine demand. Therefore, the research institutes of biological products such as Changchun, Chengdu and Lanzhou, which are under the control of Beijing Biological, have all expanded their vaccine production capacity in COVID-19 by sharing packaging.
Although the packaging companies are different, the original solution of the vaccine is still produced by Beijing Bio. Moreover, this form of sub-packaging is approved by the drug regulatory authorities. Whether it is Changchun Bio, Chengdu Bio or Lanzhou Bio, all three are the same vaccine marketing license holders, and they are all legal, so the concerns about quality or safety are completely different.
The above content comes from Baidu Encyclopedia-Changchun Changsheng Biotechnology Co., Ltd.